Background: Hysteroscopy has revolutionized the field of Gynecology and the management of many gynecological conditions. It has now become a standard part in the diagnosis of postmenopausal bleeding by the gynecological surgeons. Cost, convenience, accuracy, and patient acceptability of these procedures are clearly superior to those of traditional surgeries. As gynecologists have grown better acquainted with the benefits and techniques of operative hysteroscopy, it has become the method of choice for treatment of intrauterine pathology. Cervical ripening is a complicated process, being mediated by cytokines, growth factors, hormones and other biochemical compounds. Both dinoglandin and Misoprostol can be used for cervical ripening before introduction of hysteroscopy and hence reduce the incidence of complications. Objects: This study aims to assess the efficacy of dinoprostone compared to misoprostol in cervical ripening in nulliparous women undergoing diagnostic hysteroscopy. Methodology: a randomized controlled clinical trial comparing dinoprostone versus misoprostol for cervical ripening before diagnostic hysteroscopy in nulliparous women, it included 2 groups, 33 patients each. In the first group named (group D) dinoprostone 3 mg was applied vaginally 6 hours before diagnostic hysteroscopic procedure while in the second group named (group M) 400 mcg misoprostol was applied vaginally at the same timing. Results: There was no statistically significant difference between the groups that received misoprostol or dinoprostone with regard to age, duration of marriage, medical disorder, history of gynecological operations and type of gynecological operations. However, the use of misoprostol caused slightly less pain compared to dinoprostone but more side effects occurred with the use of misoprostol. Conclusion: There was no significant difference between dinoprostone and misoprostol in priming of cervix before diagnostic hysteroscopy in nulliparous women regarding ease of hysteroscope entry, pain or side effects.
INTRODUCTION
Hysteroscopy is one of the diagnostic methods that developed recently in gynecology. The whole uterine cavity is explored through hysteroscope. In the presense of any pathologic lesion, biopsy is taken and treatment is performed through hysteroscopy if needed (e.g. removal of submucosal myoma or endometrial polyp). Hysteroscopy has been proved to be a totally reliable method for the study of postmenopausal bleeding (1) . Although hysteroscopy has been identified as a safe and less invasive procedure, some complications such as cervical tear, bleeding, uterine perforation, pain and discomfort may occur during the procedure. Many women need dilatation prior to hysteroscopy to make the procedure more simple (2) . The incidence of these complications may decline if we use cervical ripening before the procedure. Cervical ripening is a complicated process, being mediated by hormones, cytokines, growth factors and other biochemical compounds.
For easy passage of hysteroscope, cervical ripening and cervical canal widening to a specific diameter should be done (3) . Many methods including medications have been introduced for cervical ripening. The most commonly used medication is misoprostol, a synthetic prostaglandin E1 (PGE1) analogue that is administered frequently in obstetrics and gynecology for cervical ripening, medical abortion, induction of labor, dilatation and curettage, endometrial biopsy, intrauterine device insertion, postpartum hemorrhage and myomectomy (4) . Prostaglandins have been widely used for induction of labor, particularly if the cervix is not 'favorable'. Prostaglandin E2 (PGE2 or dinoprostone) appears to be the prostaglandin of choice when used vaginally in the form of tablets, gel or pessaries. Oral prostaglandins administration is less effective and has been virtually abandoned, mainly due to its side effects on gastrointestinal 2288 tract. However, after the introduction of a new synthetic prostaglandin E1 analogue -misoprostol interest in oral prostaglandins has increased (5).
Misoprostol was first used for prevention of peptic ulcer from the use of non-steroidal antiinflammatory drugs (6) . It has been argued that administration of misoprostol before hysteroscopy makes cervical passage easier and decreases the risk of cervicouterine complications (7) .
AIM OF THE WORK
This study aims to assess the efficacy of dinoprostone compared to misoprostol in cervical ripening in nulliparous women undergoing diagnostic hysteroscopy. Office hysteroscope entry was evaluated using Likert scale, which is a method of ascribing quantitative value to qualitative data, to make it amenable to statistical analysis. A numerical value is assigned to each potential choice and a mean figure for all the responses is computed at the end of the evaluation. The final average score represents overall level of accomplishment or attitude toward the subject matter and in this study the scale was as follows; easy entry, hard entry, failed entry.
PATIENTS AND METHODS

Secondary outcomes
Pain assessment was evaluated at the end of the procedure using visual analogue scale, which is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. It is often used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms. For example, the amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain (8) .
2289
Side effects will be assessed as diarrhea, nausea, vomiting, fever, and abdominal pain.
Data Management and Analysis
The collected data was revised, coded, tabulated and introduced to a PC 
RESULTS
In this study, a sample of 66 women were included and divided equally and randomly in to two groups; group M received 400 mcg misoprostol vaginally 6 hours before their diagnostic hysteroscopy and group D received 3 mg dinoprostone vaginally 6 hours before their diagnostic hysteroscopy. There was no significant difference between the two study groups as regard to mean procedure duration, as it was 13.7±2.85 minutes for group D compared to 12.85± 2.58 minutes for group M. Also, no significant differences between the two study groups as regard to pain score, and in the need for anesthesia. There was no significant difference between the failed and succeeded cases as regard to cases' mean age and mean duration of marriage, however, a significant difference was found between the failed and succeeded cases regarding procedural duration and pain score, as they were both higher among failed group. Similarly, need for anesthesia was significantly more frequent among the failed group. There was no significant difference between the failed and succeeded cases as regard to occurrence of side effects.
DISCUSSION
Hysteroscopy is considered the gold standard for uterine cavity evaluation because it allows for direct visualization. Diagnostic hysteroscopy may be performed in the office using a small-diameter hysteroscope and saline distension, often without need for anesthesia (9) . Almost 50% of hysteroscopic complications are related to difficulty with cervical entry. Potential complications include cervical tears, creation of a false passage, perforation, bleeding, or simply difficulty in entering the internal os (between the cervix and the uterus) with the hysteroscope.
(10) Using efficient method to facilitate an easier uncomplicated entry during the hysteroscopic procedure could substantially minimize the risk of complications (11) . Cervical ripening agents include oral or vaginal prostaglandin, which can be synthetic (e.g. misoprostol) or natural (e.g. dinoprostone) and vaginal osmotic dilators, which can be naturally occurring (e.g. laminaria) or synthetic (10). Prostaglandins have been considered to be the central mediators in cervical ripening by inducing collagenolytic activity and synthesis of proteoglycans (12) , misoprostol is a prostaglandin El analogue, like PGE2, is capable of facilitation of metalloproteinase (MMP) containing leukocyte and monocyte influx into the cervix (13) , originally approved by the Food and Drug Administration (FDA) (14) . It can be administered either sublingually (15) or vaginally (16). It is inexpensive, has short half life, easily stored, and is widely available, being registered in more than 80 countries, it has been tested in randomized controlled trials (RCTs), these studies have shown that preoperative cervical ripening with misoprostol decreased both intraoperative morbidity and duration of hysteroscopy (17) . Currently, misoprostol is the drug of choice for cervical ripening; previous randomized studies have shown that preoperative cervical ripening with misoprostol decreased both intraoperative morbidity and duration of hysteroscopy (18) . Although both the sublingual Mulayim et al (15) and vaginal Darwish et al (19) routes have been proven to be effective for cervical priming before hysteroscopy, the optimal regimen and dose of misoprostol remains to be determined. This is a randomized controlled clinical trial comparing dinoprostone versus misoprostol for cervical ripening before diagnostic hysteroscopy in nulliparous women, it included 2 groups, 33 patients each. In the first group named (group D) dinoprostone 3 mg was applied vaginally 6 hours before diagnostic hysteroscopic procedure while in the second group named (group M) 400 mcg misoprostol was applied vaginally at the same timing. There was no statistically significant difference between the groups that received misoprostol or dinoprostone with regard to age, duration of marriage, medical disorder, history of gynecological operations and type of gynecological operations. In the current study, we have found that there was no significant difference between the two study groups as regard to procedure outcome; as 84.8% of group D succeeded compared to 90.9% of group M cases. Similarly, no significant difference was found between the two study groups as regard to mode of hysteroscopic entry; as 53.6% of group D was easy entry compared to 63.3% of group M. This is a disagreement with Inal et al (20) , they found that the use of vaginal dinoprostone is more effective than misoprostol for cervical ripening in nulliparous women before diagnostic hysteroscopy and the study showed that dinoprostone provides a higher level of cervical priming.
Also, our results agreed with Preutthipan and Herabutya (21) to an extent, as they found that the use of vaginal misoprostol is more effective than dinoprostone for cervical priming, but in our study this superiority did not reach a statistical significance.
In the current study, there was no significant difference between the two study groups as regard to mean procedure duration, as it was 13.7±2.85 minutes for group D compared to 12.85± 2.58 minutes for group M. Also, no significant differences between the two study groups as regard to pain score as it was 5.15±2.09 for group D compared to 4.33±1.96 for group M, and in the need for anesthesia there was also no significant differences as it was 15.2% for group D compared to 9.1% for group M. In the Inal et al (20) study there was an agreement regarding procedure duration as there was no significant differences between the two study groups but there was a disagreement regarding the need for anesthesia and cervical dilatation as it was 30% for the dinoprostone group compared to 56.7% for the misoprostol group.
In the Preutthipan and Herabutya (21) study there was an agreement with the current study and Inal et al (20) regarding procedure duration as there was no significant differences between the two study groups, but there was a disagreement between Preutthipan and Herabutya (22) and the current study regarding the need for anesthesia and cervical dilatation as it was 80.4% for the dinoprostone group compared to 70.4% for the misoprostol group.
The pain assessment using the visual analogue scale was not studied by Inal et al (20) or Preutthipan and Herabutya (21) in their studies. In the current study as regard to side effects, 2 patients complained from nausea in group D (6.1%) compared to 3 patients in group M (9.1%), none of the patients complained from vomiting in group D (0%) compared to 1 patient in group M (3%), 1 patient complained of fever in group D (3%) compared to 2 patients in group M (6.1%), 5 patients complained from abdominal pain in group D (15.2%) compared to 7 patients in group M (21.2%) and none of the patients complained from diarrhea in both study groups. As a conclusion, there was no significant differences between the two study groups regarding all these side effects. The current study was supported by Inal et al (20) as there was no significant differences between the two study groups regarding side effects. Preutthipan and Herabutya (21) suggested that there were more side effects in the misoprostol group. The significant difference of side effects between the two groups were abdominal pain, vaginal bleeding, and feeling feverish, which occurred in 36.2%, 29.6%, and 7.2% in the misoprostol group compared to 21.5%, 16.5%, and 1.3%, respectively, in the dinoprostone group.
CONCLUSION
There was no significant difference between dinoprostone and misoprostol in priming of cervix before diagnostic hysteroscopy in nulliparous women regarding ease of hysteroscope entry, pain or side effects.
